Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: Factor II versus chromogenic factor X testing

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 3, 2014, Pages 232-236

  Baumann Kreuziger, Lisa M ^a   Datta, Yvonne H ^a   Johnson, Andrew D ^b   Zantek, Nicole D ^b   Shanley, Ryan ^a   Reding, Mark T ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulation; Antiphospholipid antibody syndrome; Chromogenic factor X; Factor II; Warfarin

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 10; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTHROMBIN TIME; THROMBOSIS; BLOOD CLOTTING; DRUG EFFECTS; DRUG MONITORING; METABOLISM; MIDDLE AGED; PROCEDURES;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR X; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN; PROTHROMBIN TIME; WARFARIN;

EID: 84897474955     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000030     Document Type: Article

References (16)

1. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92:2131-2140
2. Lind SE, Callas PW, Golden EA, Joyner KA, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48-53
3. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177-185
4. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19:265-275
5. Horellou MH, Aurousseau MH, Boffa MC, Conrad J, Wiesel ML, Samama M. Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. J Med 1987; 18:199-217
6. Fleck RA, Rapaport SI, Rao LV. Antiprothrombin antibodies and the lupus anticoagulant. Blood 1988; 72:512-519
7. Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutire B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome: Influence of the lupus anticoagulant on International Normalized Ratio. Groupe Mé thodologie en Hémostase du Groupe d'Etudes sur l'Hé mostases et la Thrombose. Thromb Haemost 1998; 80:99-103
8. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115:672-678
9. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-Antibody syndrome. N Engl J Med 1995; 332:993-997
10. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyel E, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994; 71:727-730
11. Pincus K, Tata A, Watson K. Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis. Ann Pharmacother 2012; 46:873-878
12. Rosborough T, Jacobsen J, Shepherd M. Factor X and factor II activity levels do not always agree in warfarin-Treated lupus anticoagulant patients. Blood Coagul Fibrinolysis 2010; 21:242-244
13. McGlasson DL, Romick BG, Rubal BJ. Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinolysis 2008; 19:513-517
14. DiaPharma. DiaPharma Factor X package insert. http:// www.diapharma.com/uploads/insert/KDPGFXinsertR2-0606.pdf . Revision6/2006. [Accessed on 20 November 2013].
15. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306
16. Rosborough T, Jacobsen J, Shepherd M. Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administration. Blood Coagul Fibrinolysis 2009; 20:433-435.